Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI predicts infection risk after brain surgery – study aims to stop it

NCT ID NCT07378683

Disease control Sponsor: Ming Yang Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a machine learning tool can identify patients at high risk for surgical site infection after brain or spinal tumor surgery. High-risk patients will receive extra preventive care, like stronger antibiotics and nutrition support. The goal is to see if this personalized approach lowers infection rates within 90 days after surgery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Machine learning-based enhanced prevention package (tailored antibiotics, nutrition, monitoring)
What this could lead to
If successful, this could provide a practical way to cut infection rates after brain or spinal tumor surgery, improving recovery and reducing complications.
What could go wrong
This is a single-center study with 500 participants, so results may not apply to all hospitals. The model's predictions might not always be accurate, and enhanced measures could increase costs or side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 500 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2025

Expected to finish

Oct 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients with a pathologically confirmed primary or metastatic central nervous system (brain or spinal) tumor. 2. Scheduled for elective craniotomy or spinal tumor resection surgery. 3. Age ≥ 18 years. 4. Expected survival \> 3 months, and able/willing to comply with postoperative follow-up. 5. Voluntary participation and provision of written informed consent. Exclusion Criteria: 1. Presence of active systemic or local surgical site infection before surgery. 2. Use of therapeutic antibiotics for any reason within 72 hours prior to surgery. 3. Concurrent severe immunosuppressive conditions, or chronic use of high-dose immunosuppressants. 4. Pregnancy or lactation. 5. Known contraindications or severe allergy to the antibiotics planned for use in the study. 6. Any other condition that, in the investigator's judgment, may affect study participation or outcome assessment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Central nervous system tumor are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

central nervous system cancer Surgical Wound Infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Central nervous system tumor Surgical site infection (SSI)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

    RECRUITING

    Beijing, PUMC, 10010, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.